<DOC>
	<DOCNO>NCT00873119</DOCNO>
	<brief_summary>The purpose study assess efficacy safety belinostat combination carboplatin paclitaxel patient previously untreated carcinoma unknown primary .</brief_summary>
	<brief_title>Belinostat , Carboplatin Paclitaxel ( BelCaP ) Compared Carboplatin Paclitaxel Patients With Cancer Unknown Primary</brief_title>
	<detailed_description>This open-label , multinational , multicenter , randomize , comparative efficacy safety study previously untreated patient carcinoma unknown primary . Patients meet inclusion exclusion criterion randomize treatment Arm A ( BelCaP ) Arm B ( CaP ) .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms , Unknown Primary</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Belinostat</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Patients CUP primary site reveal complete history , physical examination ( include gynecological examination appropriate ) , compute tomography ( CT ) scan chest , abdomen pelvis , bilateral mammography ( woman adenocarcinoma poorly differentiate carcinoma ) , routine laboratory study ( complete blood cell count , electrolyte , urinalysis , liver renal function test ) , direct workup symptomatic area . Light microscopic pathologic diagnosis adenocarcinoma ( include poorly differentiate ) , squamous cell carcinoma , poorly differentiate carcinoma . Patients poorly differentiate carcinoma must immunohistochemical stain confirm diagnosis carcinoma , rule tumor type . Note : patient light microscopic histology diagnosis `` poorly differentiate neoplasm , otherwise classify '' fulfill criterion inclusion , unless immunohistochemical staining confirm diagnosis carcinoma . Signed consent IRB ( [ Institutional Review Board ] ) /IEC ( [ Independent ethic committee ] ) approve ICF ( [ Informed Consent Form ] ) . At least one measurable lesion accord RECIST ( [ response evaluation criterion solid tumor ] ) criterion . Note , target lesion could select within previously irradiate area newly arise clearly progress irradiation proven repeat scan Performance status Eastern Cooperative Oncology Group ( ECOG ) ≤ 2 . Age ≥ 18 year . A negative serum urine pregnancy test woman childbearing potential . Postmenopausal woman must amenorrheic ≥ 12 month consider nonchildbearing potential . Serum potassium within normal range . Acceptable coagulation status : Prothrombin time/International normalize ratio PT/INR ( [ international normalize ratio ] ) , activate partial thromboplastin time ( APTT ) ≤ 1.5 × upper limit normal ( ULN ) therapeutic range anticoagulation therapy . Acceptable liver , renal bone marrow function include follow : 1 . Bilirubin ≤ 1.5 time ULN ( liver metastasis present , ≤ 3 × ULN allow ) . 2 . Aspartate aminotransferase/serum glutamic oxaloacetic transaminase ( AST/SGOT ) , alanine amino transferase/serum glutamic pyruvic transaminase ( ALT/SGPT ) , alkaline phosphatase ≤ 3 time ULN ( liver metastasis present , ≤ 5 × ULN allow ) . 3 . An estimated creatinine clearance ≥ 45 mL/min use appropriate formula ( Appendix C , protocol version 1.0 , Appendix 16.1.1 ) , measure ethylenediaminetetraacetic acid ( EDTA ) renal clearance ≥ 45 mL/min . 4 . Absolute neutrophils count ≥ 1.5 × 109/L , platelet ≥ 100 × 109/L . 5 . Hemoglobin ≥ 9.0 g/dL ≥ 5.6 mmol/L ( patient chronic anemia due underlying disease treatment could undergo blood transfusion prior treatment order meet criterion ) . Patients well recognize subset CUP site treatment direct towards define tumor type , surgery , alternatively radiotherapy , advise : Women adenocarcinoma involve axillary lymph node . Women papillary serous carcinoma peritoneum . Women adenocarcinoma positive staining estrogen receptor ( ER ) progesterone receptor . Young men ( &lt; 45 year ) poorly differentiate carcinoma consistent extragonadal germ cell tumor ( carcinoma involve mediastinum retroperitoneum , elevate level betahuman chorionic gonadotropin alphafetoprotein ) . Men bone metastasis and/or adenocarcinoma , abnormally elevate PSA ( [ Prostate specific antigen ] ) plasma . Patients squamous cell carcinoma involve cervical lymph node , inguinal lymph node . Patients neuroendocrine carcinoma determine accord standard pathology diagnosis procedure , include stain . Patients potentially completely resectable metastatic disease , disease adequately treat radiotherapy . Patients brain meningeal metastasis . Note , patient adequately treat brain metastasis , e.g . surgically resect , adequately control radiotherapy , residual neurological symptom due metastasis steroid treatment require , could enrol . If clinical suspicion , adequate investigation perform rule brain metastasis meningeal involvement . Prior systemic antitumor therapy , include chemotherapy administer association radiotherapy sensitization , CUP . Note , prior radiotherapy surgery allow provide treatment complete least 4 week randomization . Treatment investigational agent , include nonantitumor agent , within last 4 week randomization . Coexisting active severe infection coexist medical condition assess Investigator likely interfere study procedure . Significant cardiovascular disease ( New York Heart Association Class III IV cardiac disease ) , myocardial infarction within past 6 month , unstable angina , unstable arrhythmia need antiarrhythmic therapy ( use medication control heart rate patient atrial fibrillation allow , stable medication least last month prior randomization medication list cause Torsade de Points ( Section 13.2 , Appendix B , protocol version 1.0 , Appendix 16.1.1 ) , evidence acute ischemia ECG . Marked baseline prolongation QT/QTc ( [ correct QT interval ] ) interval , i.e. , demonstration QTc interval &gt; 450 millisecond ( m ) ; Long QT Syndrome ; require use concomitant medication may cause Torsade de Pointes ( Section 13.2 , Appendix B , protocol version 1.0 , Appendix 16.1.1 ) . Altered mental status preclude understand informed consent process and/or completion necessary study procedure . History previous malignancy within 5 year exception nonmetastatic nonmelanoma skin cancer cervical carcinoma situ . Prior systemic therapy malignancy complete least 5 year randomization allow . Implemented amendment 2 ( study center France ) : History previous malignancy , irrespective time since diagnosis/treatment , exception non metastatic nonmelanoma skin cancer cervical carcinoma situ . Known hypersensitivity either platinum compound paclitaxel , component study medication , inability desensitization . Known infection HIV , know active Hepatitis B C infection . Peripheral neuropathy ≥ Grade 2 . Pregnant lactating female . Women childbearing age potential willing use effective contraception study 30 day last dose study drug . Male patient male patient female partner childbearing age potential willing use effective contraception study 30 day last dose study drug . Highly effective method birth control define result low failure rate ( i.e . le 1 % per year ) use consistently correctly implant , injectables , combine oral contraceptive , intra uterine device , sexual abstinence vasectomize partner . Patients affiliate social security ( study center France ) . Implemented amendment 1 ( study center Denmark ) : Hearing impairment assess Investigator degree treatment carboplatin initiate . Implemented amendment 1 ( study center Denmark ) : Bleeding tumor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Belinostat</keyword>
	<keyword>PXD101</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>CUP</keyword>
	<keyword>Carcinoma unknown primary</keyword>
	<keyword>Occult primary</keyword>
</DOC>